•] Shares ACRIVON THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • November 3rd, 2022 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations • New York
ACRIVON THERAPEUTICS, INC. SHARES OF COMMON STOCK, PAR VALUE $0.001 PER SHARE SALES AGREEMENTSales Agreement • December 1st, 2023 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations • New York
Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“TD Cowen”), as follows:
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 9th, 2024 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of April 8, 2024, is entered into by and among ACRIVON THERAPEUTICS, INC., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
SECURITIES PURCHASE AGREEMENT BY AND AMONG ACRIVON THERAPEUTICS, INC., AND THE PURCHASERS AS SET FORTH HEREIN April 8, 2024Securities Purchase Agreement • April 9th, 2024 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April 8, 2024, by and among Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, a “Purchaser” and together, the “Purchasers”).
COMPANY LETTERHEAD]Registration Rights Agreement • April 9th, 2024 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Subject to and in consideration of an investment in Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”), by [__] (collectively, the “Investor”), the parties to this letter hereby agree as follows:
SECOND AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENTOncosignature Companion Diagnostic Agreement • March 28th, 2024 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations
This SECOND AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENT (the “Second Amendment”) is made and entered into as of June 19, 2023 (the “Second Amendment Effective Date”) by and between:
First Amendment to ONCOSIGNATURE COMPANION DIAGNOSTIC AgreementOncosignature Companion Diagnostic Agreement • March 28th, 2023 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to Oncosignature Companion Diagnostic Agreement (the “First Amendment”) is made and entered into as of December 21, 2022 (the “First Amendment Effective Date”) by and between:
SECOND AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENTOncosignature Companion Diagnostic Agreement • August 11th, 2023 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations
This Second Amendment to Oncosignature Companion Diagnostic Agreement (the “Second Amendment”) is made and entered into as of June 19, 2023 (the “Second Amendment Effective Date”) by and between:
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 28th, 2024 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Amended and Restated Executive Employment Agreement (this “Agreement”), is entered into this 30th day of May, 2023, and is by and between Acrivon Therapeutics Inc., a Delaware corporation (“Company”), and Kristina M. Masson (“Executive”), and made effective as of June 1, 2023 (the “A&R Effective Date”).
SHARE PURCHASE AGREEMENTShare Purchase Agreement • November 17th, 2022 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations • New York
This SHARE PURCHASE AGREEMENT (this “Agreement”) is entered into as of November 14, 2022 (the “Effective Date”), by and between Chione Limited (the “Investor”), and Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”).
THIRD AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENTOncosignature Companion Diagnostic Agreement • March 28th, 2024 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations
This Third Amendment to Oncosignature Companion Diagnostic Agreement (the “Third Amendment”) is made and entered into as of December 4, 2023 (the “Third Amendment Effective Date”) by and between:
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 5th, 2023 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Amended and Restated Executive Employment Agreement (this “Agreement”), is entered into this 30th day of May, 2023, and is by and between Acrivon Therapeutics Inc., a Delaware corporation (“Company”), and Kristina M. Masson (“Executive”), and made effective as of June 1, 2023 (the “A&R Effective Date”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 28th, 2023 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Executive Employment Agreement (the “Agreement”), is made and entered into this 5th day of October, 2020 (the “Effective Date”), and is by and between Acrivon Therapeutics Inc., a Delaware corporation (“Company”), and Kristina M. Masson (“Executive”).
FOURTH AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENTOncosignature Companion Diagnostic Agreement • November 13th, 2024 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations
This FOURTH AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENT (this “Fourth Amendment”) is effective as of September 30, 2024 (the “Fourth Amendment Effective Date”) by and between:
EMPLOYMENT CONTRACT On this day this the following contract of employment (“the Agreement”) has been entered into between andEmployment Contract • June 5th, 2023 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations
Acrivon AB hereinafter referred to as (”Employer”). Kristina Masson, hereinafter referred to as (“Employee”). The Employer and the Employee are collectively referred to as (“the Parties”) and separately as (“Party”).
COMPANY LETTERHEAD]Acrivon Therapeutics, Inc. • April 9th, 2024 • Pharmaceutical preparations • Delaware
Subject to and in consideration of an investment in Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”), by [__] and/or one or more of its Affiliates (as defined below) (each, an “Investor” and together, the “Investors”), the parties to this letter hereby agree as follows:
